Predictors of response to tofacitinib or etanercept in a Phase 3 randomised, non-inferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0

作者：

Lambert, J. ^{[1
]}

Strohal, R. ^{[2
]}

de la Cruz, C. ^{[3
]}

Thaci, D. ^{[4
]}

Bachelez, H. ^{[5
]}

Iversen, L. ^{[6
]}

Rottinghaus, S. ^{[7
]}

Tallman, A. ^{[8
]}

Tan, H. ^{[7
]}

Berstein, G. ^{[9
]}

机构：

[1] Ghent Univ Hosp, Ghent, Belgium

[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria

[3] Clin Dermacross, Santiago, Chile

[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany

[5] Univ Paris Diderot, Hop St Louis, APHP, Sorbonne Paris Cite, Paris, France

[6] Aarhus Univ Hosp, Aarhus C, Denmark

[7] Pfizer Inc, Groton, CT 06340 USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Cambridge, MA USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷

关键词：

etanercept; psoriasis; tofacitinib;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P152

引用

页码：78 / 78

页数：1

共 50 条

[31] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
Bissonnette, R.
Iversen, L.
Sofen, H.
Griffiths, C. E. M.
Foley, P.
Romiti, R.
Bachinsky, M.
Rottinghaus, S. T.
Tan, H.
Proulx, J.
Valdez, H.
Gupta, P.
Mallbris, L.
Wolk, R.
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1395 - 1406
[32] Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
Di Lernia, V.
Bardazzi, F.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 533 - 539
[33] Exploring the synergistic effects of cytokines as predictors of response to apremilast in patients with moderate to severe plaque psoriasis
Garcet, S.
Correa-da Rosa, J.
Nograles, K.
Schafer, P.
Krueger, J.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S42 - S42
[34] Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept
Griffiths, C. E. M.
Sterry, W.
Brock, F.
Dilleen, M.
Stefanidis, D.
Germain, J. M.
Mallbris, L.
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) : 230 - 238
[35] A 12-week phase 3 study of efficacy and safety of etanercept therapy in children and adolescents with moderate to severe plaque psoriasis
Paller, Amy
Siegfried, Elaine
Langley, Richard
Gottlieb, Alice
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB195 - AB195
[36] Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis
Fitz, L.
Zhang, W.
Soderstrom, C.
Fraser, S.
Lee, J.
Quazi, A.
Wolk, R.
Mebus, C. A.
Valdez, H.
Berstein, G.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (07) : 790 - 797
[37] Serum IL-17A at baseline correlates with clinical response to tofacitinib and etanercept in moderate to severe psoriasis
Berstein, G.
Zhang, W.
Soderstrom, C.
Fraser, S.
Lee, J.
Quazi, A.
Wolk, R.
Mebus, C.
Valdez, H.
Fitz, L.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S33 - S33
[38] Characterization of etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients with moderate to severe plaque psoriasis
Langley, Richard G.
Kasichayanula, Sree
Trivedi, Mona
Aras, Gary
Kaliyaperumal, Arunan
Yuraszeck, Theresa
Gibbs, Megan
Kricorian, Greg
Paller, Amy S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB67 - AB67
[39] Early clinical response as a predictor of subsequent response to tofacitinib treatment: Results from two phase 3 studies of subjects with moderate to severe plaque psoriasis
Tan, Huaming
Valdez, Hernan
Wolk, Robert
Tallman, Anna
Gordon, Kenneth B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB244 - AB244
[40] Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis
Tan, Huaming
Valdez, Hernan
Griffiths, Chris E. M.
Mrowietz, Ulrich
Tallman, Anna
Wolk, Robert
Gordon, Kenneth
JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (01) : 3 - 7

← 1 2 3 4 5 →